©2024 Stanford Medicine
Study of Personalized Immunotherapy in Adults With Metastatic Colorectal Cancer
Not Recruiting
Trial ID: NCT03189030
Purpose
This study will evaluate the safety and tolerability of a personalized live, attenuated,
double-deleted Listeria monocytogenes (pLADD) treatment in adults with metastatic colorectal
cancer.
Official Title
A Phase 1 Safety and Tolerability Study of Personalized Live, Attenuated, Double-Deleted Listeria Monocytogenes (pLADD) Immunotherapy in Adults With Metastatic Colorectal Cancer
Stanford Investigator(s)
George A. Fisher Jr.
Colleen Haas Chair in the School of Medicine
Tyler Johnson
Clinical Associate Professor, Medicine - Oncology
Eligibility
Inclusion Criteria:
- metastatic colorectal cancer (mCRC) that is microsatellite stable (MSS)
- able to provide adequate tumor tissue from at least 1 accessible tumor site
- completed or have developed intolerance to a course of oxaliplatin- or
irinotecan-based frontline therapy at Screening
- on maintenance standard-of-care chemotherapies or on treatment holiday
- Eastern Cooperative Oncology Group (ECOG) 0 or 1
- adequate organ function
- progression of disease at the time of Enrollment
Exclusion Criteria:
- BRAF V600E mutation
- known allergy to both penicillin and sulfa drugs
- implanted devices that cannot be easily removed
- immunodeficiency, immune compromised state or receiving immunosuppressive therapy
Intervention(s):
biological: pLADD
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061